Induction of a-A-Acetylgalactosamine-O-Serine/Threonine (Tn) Antigen-mediated Cellular Immune Response for Active Immunotherapy in Mice

Cancer Research

Volumn 51, Issue 5, 1991, Pages 1406-1411

  Singhal, Anil ^a,b   Fohn, Melinda ^a,b   Hakomori, Sen itiroh ^a,b  

^a The Biomembrane Institute   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; MUCIN;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMAL; ANTIBODIES; ANTIGENS, NEOPLASM; DISACCHARIDES; FEMALE; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MUCINS; NEOPLASMS, EXPERIMENTAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES;

EID: 0025777493     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Foley, E. J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res., 13: 835-837, 1953.
2. Prehn, R. T., and Main, J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst., 18: 769-778, 1957.
3. Klein, G., Sjogren, H. O., Klein, E., and Hellstrom, K-E. Demonstration of resistance against MCA induced sarcomas in the primary autochthonous host. Cancer Res., 20: 1561-1572, I960.
4. Bystryn, J. C., Jacobsen, S., Harris, M., Roses, D., Speyer, J., and Levin, M. Preparation and characterization of a polyvalent human melanoma antigen vaccine. J. Biol. Resp. Modif., 5: 211-224, 1986.
5. Mitchell, M. S., Kan-Mitchell, J., Kempf, R. A., Harel, W., Shan, H., and Lind, S. Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res., 48: 5883-5893, 1988.
6. Berd, D., Maguire, H. C. Jr., and Mastrangelo, M. J. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res., 46: 2572-2577, 1986.
7. Neidhart, J. A., Murphy, S. G., Hennick, L. A., and Wise, H. A. Active specific immunotherapy of stage IV renal carcinoma with aggregated tumor antigen adjuvant. Cancer (Phila.), 46: 1128-1134, 1980.
8. Sahasrabudhe, D. M., de Kernion, J. B., Pontes, J. E., McCune, C. S., Ryan, D. M., and O'Donnell, R. W. Specific immunotherapy with suppressor function inhibition for metastatic renal cell carcinoma. J. Biol. Resp. Modif., 5:581-594, 1986.
9. Hoover, H. C., Jr., Surdyke, M. G., Dangel, R. B., Peters, L. C., and Hanna, M., Jr. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer (Phila.), 55: 1236-1243, 1985.
10. Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res., 52: 257-331, 1989.
11. Singhal, A., and Hakomori, S. Molecular changes in carbohydrate antigens associated with cancer. BioEssays, 12: 223-230, 1990.
12. Livingston, P. O., Natoli, E. J., Calves, M. J., Stockert, E., Oettgen, H. F., and Old, L. J. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA, 84: 2911-2915, 1987.
13. Livingston, P. O., Ritter, G., Srivastava, P., Padavan, M., Calves, M. J., Oettgen, H. F., and Old, L. J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified Gm2 ganglioside. Cancer Res., 49: 7045-7050, 1989.
14. Springer, G. F. T and Tn, general carcinoma autoantigens. Science (Washington DC), 224: 1198-1206, 1984.
15. Henningsson, C. M., Selvaraj, S., MacLean, G. D., Suresh, M. R., Noujaim, A. A., and Longenecker, B. M. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol. Immunother., 25: 231-241, 1987.
16. Fung, P. V. S., Madej, M., Koganty, R. R., and Longenecker, B. M. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res., 50: 4308-4314, 1990.
17. Hirohashi, S., Clausen, H., Vamada, T., Shimosato, Y., and Hakomori, S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LC-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc. Natl. Acad. Sci. USA, 82:7039-7043, 1985.
18. Hauschka, T. S., Weiss, L., Holdridge, B. A., Cudney, T. L., Zumpft, M., and Planinsek, J. A. Karyotypic and surface features of murine T43 carcinoma cells during immunoselection in mice and rats. J. Natl. Cancer Inst., 7: 343-359, 1971.
19. Kjeldsen, T., Clausen, H., Hirohashi, S., Ogawa, T., lijima, H., and Hakomori, S. Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2→6- α-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res., 48: 2214-2220, 1988.
20. Clausen, H., Stroud, M. R., Parker, J., Springer, G., and Hakomori, S. Monoclonal antibodies directed to the blood group A associated structure, galactosyl-A: specificity and relation to the Thomsen-Friedenreich antigen. Mol. Immunol., 25: 199-204, 1988.
21. Hill, H. D., Reynolds, J. A., and Hill, R. L. Purification, composition, molecular weight, and subunit structure of ovine submaxillary mucin. J. Biol. Chem., 252:3791-3798, 1977.
22. Bhavanandan, V. P., and Hagarty, J. D. Identification of the mucin core protein by cell-free translation of messenger RNA from bovine submaxillary glands. J. Biol. Chem., 262: 5913-5917, 1987.
23. Codington, C. F., Sanford, B. H., and Jeanloz, R. W. Cell surface glycoproteins of two sublines of the T43 tumor. J. Natl. Cancer Inst., 51: 585-591, 1973.
24. Codington, C. F., Yamazaki, T., van den Eijnden, D. H., Evans, E. A., and Jeanloz, R. W. Unequivocal evidence for a ß-p-configuration of the galactose residue in the disaccharide chain of epiglycanin, the major glycoprotein of the T43-Ha tumor cell. FEBS Lett., 99: 70-72, 1979.
25. Harada, Y., Sakatsume, M., Nores, G. A., Hakomori, S., and Taniguchi, M. Density of GM3 with normal primary structure determines mouse melanoma antigenicity: a new concept of tumor antigen. Jpn. J. Cancer Res., 80: 988-992, 1989.
26. Bellamy, A., Davidson, A. N., and Feldmann, M. Derivation of gangliosidespecific T cell lines of suppressor or helper phenotype from cerebrospinal fluid from multiple sclerosis patients. J. Neuroimmunol., 12: 107-120, 1986.
27. Black, P. L., Vitetta, E. S., Forman, J., Kang, C-Y., May, R. D., and Uhr, J. W. Role of glycosylation in the H-2 restricted cytosis of virus-infected cells. Eur. J. Immunol., 11:48-55, 1981.
28. Matsuura, H., Takio, K., Titani, K., Greene, T., Levery, S. B., Salyan, M. E. K., and Hakomori, S. The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6: unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide. J. Biol. Chem., 263: 3314-3322, 1988.
29. Matsuura, H., Greene, T., and Hakomori, S. An α-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J. Biol. Chem., 264: 10472-10476, 1989.
30. Barnd, D. L., Lan, M. S., Metzgar, R. S., and Finn, O. J. Specific major histocompatibility complex: unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 86: 7159-7163, 1989.
31. Fleischer, B. Acquisition of specific cytotoxic activity by human T4+ T lymphocytes in culture. Nature (Lond.), 308: 365-367, 1984.
32. Golding, H., Munitz, T. 1., and Singer, A. Characterization of antigen-specific, la restricted, L3T4 cytolytic T lymphocytes and assessment of thymic influence on their self specificity. J. Exp. Med., 162: 943-961, 1985.
33. Nakamura, M., Ross, D. T., Briner, T. J., and Gefter, M. L. Cytotoxic activity of antigen-specific T cells with helper phenotype. J. Immunol., 136: 44-47, 1986.
34. Erb, P., Grogg, D., Troxler, M., Kennedy, M., and Fluri, M. CD4 T cell-mediated killing of MHC class Il-positive antigen-presenting cells: I. Characterization of target cell recognition by in vivo or in vitro activated CD4' killer T cells. J. Immunol., 144: 790-795, 1990.